PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla” or the “Company”), a leader in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX-class compounds, today announced that it has executed a definitive SPV Formation, Shareholder and License Agreement (the “Definitive Agreement”) with Aluvaris Inc. (“Aluvaris”) and Diteba Inc. (“Diteba”). The Definitive Agreement establishes a jointly-owned special purpose vehicle called Restora Neurosciences (the “Restora” or the “SPV”) to lead the clinical and regulatory development of APA-01, the Company's patented novel MDXX molecule, with the explicit objective of filing a first Investigational New Drug application with the U.S. Food and Drug Administration.